

POLISH FINANCIAL SUPERVISION AUTHORITY

Current Report No. 13 / 2020

Date of preparation: 2020-02-26

Abbreviated name of the Issuer

MABION S.A.

Subject matter:

Update on the registration procedure for the marketing authorisation of MabionCD20 by the European Medicines Agency

Legal basis

Article 17(1) MAR - confidential information.

Content of the report:

In reference to Current Report No. 11/2020 of February 13th, 2020 and earlier communication in the scope of the application by Mabion S.A. ("Company") for the marketing authorization of a medicine under the working name of MabionCD20 by the European Medicines Agency (EMA), the Management Board of the Company hereby informs that on February 26th, 2020 it participated, together with a team of specialists, in the meeting of the Committee for Medicinal Products for Human Use (CHMP) and presented the issues indicated by the EMA in the invitation received on February 13th, 2020 (oral explanation).

On further formally binding and relevant events as part of the registration procedure of MabionCD20 in the EMA, the Company will keep you informed on an ongoing basis.

.